Colecalciferol/ibandronic acid - Alvogen Korea

Drug Profile

Colecalciferol/ibandronic acid - Alvogen Korea

Alternative Names: DP-R 206

Latest Information Update: 16 Nov 2016

Price : $50

At a glance

  • Originator DreamPharma Corporation
  • Developer Alvogen Korea
  • Class Adjuvants; Antihypercalcaemics; Bisphosphonates; Calcium regulators; Cholestenes; Osteoporosis therapies; Small molecules; Sterols; Vitamin D analogues
  • Mechanism of Action Bone resorption factor inhibitors; Dimethylallyltranstransferase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Postmenopausal osteoporosis

Most Recent Events

  • 18 Feb 2016 Phase-III development is still ongoing in South Korea (NCT01581320)
  • 01 Jan 2013 Phase-III clinical trials in Postmenopausal osteoporosis (including elderly) in South Korea (unspecified route)
  • 06 Apr 2012 Phase-I clinical trials in Postmenopausal osteoporosis (in volunteers) in South Korea (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top